ZA202206740B - Interleukin 2 chimeric constructs - Google Patents

Interleukin 2 chimeric constructs

Info

Publication number
ZA202206740B
ZA202206740B ZA2022/06740A ZA202206740A ZA202206740B ZA 202206740 B ZA202206740 B ZA 202206740B ZA 2022/06740 A ZA2022/06740 A ZA 2022/06740A ZA 202206740 A ZA202206740 A ZA 202206740A ZA 202206740 B ZA202206740 B ZA 202206740B
Authority
ZA
South Africa
Prior art keywords
interleukin
chimeric constructs
chimeric
constructs
Prior art date
Application number
ZA2022/06740A
Inventor
David Klatzmann
Nicolas Billiald
Thomas Vazquez
Jérémie Mariau
Original Assignee
Iltoo Pharma
Univ Sorbonne
Inst Nat Sante Rech Med
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iltoo Pharma, Univ Sorbonne, Inst Nat Sante Rech Med, Hopitaux Paris Assist Publique filed Critical Iltoo Pharma
Publication of ZA202206740B publication Critical patent/ZA202206740B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
ZA2022/06740A 2019-12-12 2022-06-17 Interleukin 2 chimeric constructs ZA202206740B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306637 2019-12-12
PCT/EP2020/085830 WO2021116444A1 (en) 2019-12-12 2020-12-11 Interleukin 2 chimeric constructs

Publications (1)

Publication Number Publication Date
ZA202206740B true ZA202206740B (en) 2023-06-28

Family

ID=69232735

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/06740A ZA202206740B (en) 2019-12-12 2022-06-17 Interleukin 2 chimeric constructs

Country Status (12)

Country Link
US (1) US20230036793A1 (en)
EP (1) EP4073094A1 (en)
JP (1) JP2023505590A (en)
KR (1) KR20220139293A (en)
CN (1) CN115190885A (en)
AU (1) AU2020401357A1 (en)
BR (1) BR112022011414A2 (en)
CA (1) CA3159468A1 (en)
IL (1) IL293628A (en)
MX (1) MX2022007203A (en)
WO (1) WO2021116444A1 (en)
ZA (1) ZA202206740B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3233644A1 (en) * 2021-10-06 2023-04-13 David Klatzmann Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
FI82266C (en) 1982-10-19 1991-02-11 Cetus Corp Process for Preparation of IL-2 Mutein
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
DZ2788A1 (en) 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
FR2869323B1 (en) * 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne USE OF THE GENE ENCODING THE BETA CHAIN OF THE PROTEIN C4BP IN THE PRODUCTION OF RECOMBINANT DIMERIC PROTEINS
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
US8437577B2 (en) 2009-03-05 2013-05-07 Tektronix, Inc. Methods and systems for image registration
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
SG11201700514SA (en) 2014-07-21 2017-02-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN108135841B (en) 2015-10-22 2024-03-05 艾尔图制药公司 Pharmaceutical compositions of IL-2
JP7422480B2 (en) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation

Also Published As

Publication number Publication date
US20230036793A1 (en) 2023-02-02
EP4073094A1 (en) 2022-10-19
KR20220139293A (en) 2022-10-14
MX2022007203A (en) 2022-10-18
CN115190885A (en) 2022-10-14
BR112022011414A2 (en) 2022-08-30
WO2021116444A1 (en) 2021-06-17
JP2023505590A (en) 2023-02-09
AU2020401357A1 (en) 2022-07-21
IL293628A (en) 2022-08-01
CA3159468A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
IL276831A (en) Inducible chimeric cytokine receptors
ZA202206740B (en) Interleukin 2 chimeric constructs
IL285162A (en) Survival-targeting chimeric (surtac) molecules
IL278061A (en) Anti-ror antibody constructs
IL287183A (en) Homx 1 inducers
IL279469A (en) Chimeric growth factor receptors
IL285230A (en) Chimeric cytokine receptors
IL291282A (en) Chimeric cytokine receptors
IL281088A (en) Flt3l-based chimeric proteins
GB202012181D0 (en) Chimeric receptor
IL285909A (en) Anti-bcma chimeric antigen receptors
IL292065A (en) Variant igf2 constructs
IL272475A (en) Immunodeficient mice expressing human interleukin 15
GB201801831D0 (en) Chimeric receptor
GB202007655D0 (en) Chimeric nkg2d protein
GB201900665D0 (en) 06557607002
IL290629A (en) Flexible cryoprobe
GB201906126D0 (en) Chimeric protein
IL282230A (en) Chimeric molecules
PL3800414T3 (en) Heater
IL277859A (en) Chimeric notch receptors
EP3983660C0 (en) Connecting rod assembly
SG10202000977XA (en) Brush assembly
EP4034146A4 (en) Conjugated chimeric proteins
IL283568A (en) Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells